These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10494785)

  • 1. Thrombostatin inhibits induced canine coronary thrombosis.
    Hasan AA; Rebello SS; Smith E; Srikanth S; Werns S; Driscoll E; Faul J; Brenner D; Normolle D; Lucchesi BR; Schmaier AH
    Thromb Haemost; 1999 Sep; 82(3):1182-7. PubMed ID: 10494785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
    Hasa AA; Schmaier AH; Warnock M; Normolle D; Driscoll E; Lucchesi BR; Werns SW
    Thromb Haemost; 2001 Nov; 86(5):1296-304. PubMed ID: 11816721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury.
    Prieto AR; Ma H; Huang R; Khan G; Schwartz KA; Hage-Korban EE; Schmaier AH; Davis JM; Hasan AA; Abela GS
    Cardiovasc Res; 2002 Mar; 53(4):984-92. PubMed ID: 11922908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.
    Murphey LJ; Malave HA; Petro J; Biaggioni I; Byrne DW; Vaughan DE; Luther JM; Pretorius M; Brown NJ
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1287-92. PubMed ID: 16772538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
    Nieman MT; Warnock M; Hasan AA; Mahdi F; Lucchesi BR; Brown NJ; Murphey LJ; Schmaier AH
    J Pharmacol Exp Ther; 2004 Nov; 311(2):492-501. PubMed ID: 15210836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
    Nieman MT; Burke F; Warnock M; Zhou Y; Sweigart J; Chen A; Ricketts D; Lucchesi BR; Chen Z; Di Cera E; Hilfinger J; Kim JS; Mosberg HI; Schmaier AH
    J Thromb Haemost; 2008 May; 6(5):837-45. PubMed ID: 18315550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits.
    Papamichael ND; Stathopoulou EM; Roussa VD; Tsironis LD; Kotsia AP; Stanica RM; Moussis V; Tsikaris V; Katsouras CS; Tselepis AD; Michalis LK
    J Pharmacol Exp Ther; 2009 May; 329(2):634-40. PubMed ID: 19244095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides.
    Connolly TM; Condra C; Feng DM; Cook JJ; Stranieri MT; Reilly CF; Nutt RF; Gould RJ
    Thromb Haemost; 1994 Oct; 72(4):627-33. PubMed ID: 7878643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
    Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant concentrations of dopamine do not amplify agonist-induced human platelet Ca2+ mobilization or GP IIb IIIa activation and do not accelerate acute coronary thrombosis in dogs.
    Sill JC; Bertha B; Berger I; Southorn V; Folts J
    J Cardiovasc Pharmacol; 2009 Mar; 53(3):246-52. PubMed ID: 19247190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
    Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
    J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.